Literature DB >> 28082452

Sphingosine-1-phosphate signalling-a key player in the pathogenesis of Angiotensin II-induced hypertension.

Anja Meissner1, Francesc Miro2,3, Francesc Jiménez-Altayó4, Andrés Jurado3, Elisabet Vila4, Anna M Planas1,3.   

Abstract

AIMS: Hypertension is a complex condition involving functional and structural alterations of the microvasculature and an activation of the immune system. T-lymphocytes play a crucial role during the development of hypertension in experimental models, yet the underlying mechanisms remain elusive. Lymphocyte egress from lymph nodes is controlled by sphingosine-1-phosphate (S1P), a natural lipid mediator regulating immune cell and vascular function in health and disease. We therefore investigated the involvement of S1P signalling in the pathogenesis of hypertension. METHODS AND
RESULTS: Angiotensin-II (AngII) treatment resulted in high blood pressure (BP) associated to increased plasma S1P and circulating T-cell counts. T-cell egress from lymph nodes was found to be a critical initial step for the onset of hypertension as fingolimod, a S1P-receptor agonist sequestering lymphocytes in the lymph nodes and inducing lymphopenia, blunted BP responses to AngII. Furthermore, activity of S1P-generating enzyme type 2 (SphK2) in haematopoietic cells critically contributed to AngII-induced lymphocyte mobilization from the lymph nodes as SphK2-/- mice and mice where SphK2 was ablated only in the haematopoietic system presented an accumulation of T-cells in mesenteric lymph nodes and a blunted BP response. In addition, deregulation of vascular SphK2 expression associated to a thrombo-inflammatory phenotype of the microvasculature, and to functional alterations of small resistance arteries.
CONCLUSION: The presented results point to a critical involvement of S1P and its signalling axis in the pathogenesis of hypertension. Specifically, SphK2 evolves as key player in immune cell trafficking and vascular dysfunction contributing to the development of overt hypertension. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author 2016. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Blood pressure; Endothelial dysfunction; Inflammation; Microvasculature; Sphingosine-1-phosphate (S1P)

Mesh:

Substances:

Year:  2017        PMID: 28082452     DOI: 10.1093/cvr/cvw256

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  21 in total

Review 1.  The emerging alliance of sphingosine-1-phosphate signalling and immune cells: from basic mechanisms to implications in hypertension.

Authors:  Nicholas Don-Doncow; Yun Zhang; Hana Matuskova; Anja Meissner
Journal:  Br J Pharmacol       Date:  2018-07-03       Impact factor: 8.739

2.  Splenocyte transfer exacerbates salt-sensitive hypertension in rats.

Authors:  Daniel J Fehrenbach; John Henry Dasinger; Hayley Lund; Jeylan Zemaj; David L Mattson
Journal:  Exp Physiol       Date:  2020-03-17       Impact factor: 2.969

Review 3.  Malaria link of hypertension: a hidden syndicate of angiotensin II, bradykinin and sphingosine 1-phosphate.

Authors:  Gunanidhi Dhangadamajhi; Shailja Singh
Journal:  Hum Cell       Date:  2021-03-08       Impact factor: 4.174

Review 4.  Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and Pathophysiology.

Authors:  Steven J Forrester; George W Booz; Curt D Sigmund; Thomas M Coffman; Tatsuo Kawai; Victor Rizzo; Rosario Scalia; Satoru Eguchi
Journal:  Physiol Rev       Date:  2018-07-01       Impact factor: 37.312

Review 5.  Sphingolipid Metabolism and Signaling in Endothelial Cell Functions.

Authors:  Linda Sasset; Annarita Di Lorenzo
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

Review 6.  Effects of Menopause in Women With Multiple Sclerosis: An Evidence-Based Review.

Authors:  Riley Bove; Annette Okai; Maria Houtchens; Birte Elias-Hamp; Alessandra Lugaresi; Kerstin Hellwig; Eva Kubala Havrdová
Journal:  Front Neurol       Date:  2021-03-19       Impact factor: 4.003

7.  CO-releasing molecules CORM2 attenuates angiotensin II-induced human aortic smooth muscle cell migration through inhibition of ROS/IL-6 generation and matrix metalloproteinases-9 expression.

Authors:  Ming-Horng Tsai; Chiang-Wen Lee; Lee-Fen Hsu; Shu-Yu Li; Yao-Chang Chiang; Ming-Hsueh Lee; Chun-Han Chen; Hwey-Fang Liang; Jia-Mei How; Pey-Jium Chang; Ching-Mei Wu; I-Ta Lee
Journal:  Redox Biol       Date:  2017-03-01       Impact factor: 11.799

8.  Th1-type immune responses to Porphyromonas gingivalis antigens exacerbate angiotensin II-dependent hypertension and vascular dysfunction.

Authors:  Marta Czesnikiewicz-Guzik; Ryszard Nosalski; Tomasz P Mikolajczyk; Francesca Vidler; Tomasz Dohnal; Elzbieta Dembowska; Delyth Graham; David G Harrison; Tomasz J Guzik
Journal:  Br J Pharmacol       Date:  2018-12-26       Impact factor: 8.739

9.  T-Cell Accumulation in the Hypertensive Brain: A Role for Sphingosine-1-Phosphate-Mediated Chemotaxis.

Authors:  Nicholas Don-Doncow; Lotte Vanherle; Yun Zhang; Anja Meissner
Journal:  Int J Mol Sci       Date:  2019-01-28       Impact factor: 5.923

Review 10.  Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms.

Authors:  John R Petrie; Tomasz J Guzik; Rhian M Touyz
Journal:  Can J Cardiol       Date:  2017-12-11       Impact factor: 5.223

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.